Please login to the form below

Not currently logged in
Email:
Password:

Pneumococcal vaccine

This page shows the latest Pneumococcal vaccine news and features for those working in and with pharma, biotech and healthcare.

Pfizer to evaluate its pneumococcal vaccine alongside COVID-19 booster jab

Pfizer to evaluate its pneumococcal vaccine alongside COVID-19 booster jab

Pfizer has launched a new study of its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) along with a booster dose of its BioNTech-partnered COVID-19 jab. ... 20vPnC includes capsular polysaccharide conjugates for the 13 serotypes in Pfizer’s

Latest news

More from news
Approximately 1 fully matching, plus 39 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    pneumococcal vaccine due to be filed next year that would extend its $3.4bn Prevnar franchise, a Clostridium difficile vaccine in phase 3 and JAK inhibitors for atopic dermatitis and alopecia.

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    26.6. ‡SK Chemicals/ Sanofi Pasteur. Collaboration. Pneumococcal conjugate vaccine (PCV). 23.

  • A tailored approach to the BRIC markets A tailored approach to the BRIC markets

    In 2009, GSK signed a 1.5bn deal with the Brazilian government to provide Syflorix, its vaccine for paediatric pneumococcal disease, at around a third of the price it charged in ... Europe. The deal guaranteed GSK a set price and set volumes for the

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...